{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T10:23:18Z","timestamp":1790504598696,"version":"4.1.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,5,25]],"date-time":"2018-05-25T00:00:00Z","timestamp":1527206400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,5,25]],"date-time":"2018-05-25T00:00:00Z","timestamp":1527206400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>As one of the most fatal malignancies, pancreatic ductal adenocarcinoma (PDAC) has significant resistance to the currently available treatment approaches. Gemcitabine, the standard chemotherapeutic agent for locally advanced and metastatic PDAC, has limited efficacy, which is attributed to innate\/acquired resistance and the activation of prosurvival pathways. Here, we investigated the <jats:italic>in vitro<\/jats:italic> efficacy of I-BET762, an inhibitor of the bromodomain and extraterminal (BET) family of proteins, in treating PDAC cell lines alone and in combination with gemcitabine (GEM). The effect of these two agents was also examined in xenograft PDAC tumors in mice. We found that I-BET762 induced cell cycle arrest in the G0\/G1 phase and cell death and suppressed cell proliferation and metastatic stem cell factors in PDAC cells. In addition, the BH3-only protein Bim, which is related to chemotherapy resistance, was upregulated by I-BET762, which increased the cell death triggered by GEM in PDAC cells. Moreover, GEM and I-BET762 exerted a synergistic effect on cytotoxicity both <jats:italic>in vitro<\/jats:italic> and <jats:italic>in vivo<\/jats:italic>. Furthermore, Bim is necessary for I-BET762 activity and modulates the synergistic effect of GEM and I-BET762 in PDAC. In conclusion, we investigated the effect of I-BET762 on PDAC and suggest an innovative strategy for PDAC treatment.<\/jats:p>","DOI":"10.1038\/s41598-018-26496-0","type":"journal-article","created":{"date-parts":[[2018,5,18]],"date-time":"2018-05-18T17:45:04Z","timestamp":1526665504000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["RETRACTED ARTICLE: The BET inhibitor I-BET762 inhibits pancreatic ductal adenocarcinoma cell proliferation and enhances the therapeutic effect of gemcitabine"],"prefix":"10.1038","volume":"8","author":[{"given":"Fang","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiansheng","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenhai","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Futao","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,5,25]]},"reference":[{"key":"26496_CR1","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/nrc.2016.66","volume":"16","author":"A Makohon-Moore","year":"2016","unstructured":"Makohon-Moore, A. & Iacobuzio-Donahue, C. A. Pancreatic cancer biology and genetics from an evolutionary perspective. Nature reviews. Cancer 16, 553\u2013565, https:\/\/doi.org\/10.1038\/nrc.2016.66 (2016).","journal-title":"Nature reviews. Cancer"},{"key":"26496_CR2","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1177\/1758834014564775","volume":"7","author":"A Teague","year":"2015","unstructured":"Teague, A., Lim, K. H. & Wang-Gillam, A. Advanced pancreatic adenocarcinoma: a review of current treatment strategies and developing therapies. Therapeutic advances in medical oncology 7, 68\u201384, https:\/\/doi.org\/10.1177\/1758834014564775 (2015).","journal-title":"Therapeutic advances in medical oncology"},{"key":"26496_CR3","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.disamonth.2013.08.001","volume":"59","author":"T Muniraj","year":"2013","unstructured":"Muniraj, T., Jamidar, P. A. & Aslanian, H. R. Pancreatic cancer: a comprehensive review and update. Disease-a-month: DM 59, 368\u2013402, https:\/\/doi.org\/10.1016\/j.disamonth.2013.08.001 (2013).","journal-title":"Disease-a-month: DM"},{"key":"26496_CR4","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.2217\/fon-2016-0010","volume":"12","author":"D Ansari","year":"2016","unstructured":"Ansari, D. et al. Pancreatic cancer: yesterday, today and tomorrow. Future oncology 12, 1929\u20131946, https:\/\/doi.org\/10.2217\/fon-2016-0010 (2016).","journal-title":"Future oncology"},{"key":"26496_CR5","doi-asserted-by":"publisher","first-page":"27","DOI":"10.5306\/wjco.v7.i1.27","volume":"7","author":"R Spadi","year":"2016","unstructured":"Spadi, R. et al. Current therapeutic strategies for advanced pancreatic cancer: A review for clinicians. World journal of clinical oncology 7, 27\u201343, https:\/\/doi.org\/10.5306\/wjco.v7.i1.27 (2016).","journal-title":"World journal of clinical oncology"},{"key":"26496_CR6","doi-asserted-by":"publisher","first-page":"315","DOI":"10.3892\/mco.2015.716","volume":"4","author":"J Gong","year":"2016","unstructured":"Gong, J., Tuli, R., Shinde, A. & Hendifar, A. E. Meta-analyses of treatment standards for pancreatic cancer. Molecular and clinical oncology 4, 315\u2013325, https:\/\/doi.org\/10.3892\/mco.2015.716 (2016).","journal-title":"Molecular and clinical oncology"},{"key":"26496_CR7","first-page":"70","volume":"28","author":"R Thota","year":"2014","unstructured":"Thota, R., Pauff, J. M. & Berlin, J. D. Treatment of metastatic pancreatic adenocarcinoma: a review. Oncology 28, 70\u201374 (2014).","journal-title":"Oncology"},{"key":"26496_CR8","doi-asserted-by":"publisher","first-page":"9297","DOI":"10.3748\/wjg.v21.i31.9297","volume":"21","author":"A Cid-Arregui","year":"2015","unstructured":"Cid-Arregui, A. & Juarez, V. Perspectives in the treatment of pancreatic adenocarcinoma. World journal of gastroenterology 21, 9297\u20139316, https:\/\/doi.org\/10.3748\/wjg.v21.i31.9297 (2015).","journal-title":"World journal of gastroenterology"},{"key":"26496_CR9","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1159\/000447739","volume":"94","author":"V Ellenrieder","year":"2016","unstructured":"Ellenrieder, V., Konig, A. & Seufferlein, T. Current Standard and Future Perspectives in First- and Second-Line Treatment of Metastatic Pancreatic Adenocarcinoma. Digestion 94, 44\u201349, https:\/\/doi.org\/10.1159\/000447739 (2016).","journal-title":"Digestion"},{"issue":"Suppl 1","key":"26496_CR10","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1159\/000201390","volume":"57","author":"U Sulkowski","year":"1996","unstructured":"Sulkowski, U. Standards and perspectives in the diagnosis and treatment of pancreatic adenocarcinoma. Digestion 57(Suppl 1), 34\u201335 (1996).","journal-title":"Digestion"},{"key":"26496_CR11","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.1002\/ijc.24573","volume":"125","author":"SP Hong","year":"2009","unstructured":"Hong, S. P., Wen, J., Bang, S., Park, S. & Song, S. Y. CD44-positive cells are responsible for gemcitabine resistance in pancreatic cancer cells. International journal of cancer 125, 2323\u20132331, https:\/\/doi.org\/10.1002\/ijc.24573 (2009).","journal-title":"International journal of cancer"},{"key":"26496_CR12","doi-asserted-by":"publisher","first-page":"75081","DOI":"10.18632\/oncotarget.12057","volume":"7","author":"JK Park","year":"2016","unstructured":"Park, J. K. et al. The anti-fibrotic effect of GV1001 combined with gemcitabine on treatment of pancreatic ductal adenocarcinoma. Oncotarget 7, 75081\u201375093, https:\/\/doi.org\/10.18632\/oncotarget.12057 (2016).","journal-title":"Oncotarget"},{"key":"26496_CR13","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1172\/JCI73455","volume":"124","author":"EJ Koay","year":"2014","unstructured":"Koay, E. J. et al. Transport properties of pancreatic cancer describe gemcitabine delivery and response. The Journal of clinical investigation 124, 1525\u20131536, https:\/\/doi.org\/10.1172\/JCI73455 (2014).","journal-title":"The Journal of clinical investigation"},{"key":"26496_CR14","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s12038-016-9600-6","volume":"41","author":"B Padmanabhan","year":"2016","unstructured":"Padmanabhan, B., Mathur, S., Manjula, R. & Tripathi, S. Bromodomain and extra-terminal (BET) family proteins: New therapeutic targets in major diseases. Journal of biosciences 41, 295\u2013311 (2016).","journal-title":"Journal of biosciences"},{"key":"26496_CR15","doi-asserted-by":"publisher","unstructured":"Taniguchi, Y. The Bromodomain and Extra-Terminal Domain (BET) Family: Functional Anatomy of BET Paralogous Proteins. International journal of molecular sciences 17, https:\/\/doi.org\/10.3390\/ijms17111849 (2016).","DOI":"10.3390\/ijms17111849"},{"key":"26496_CR16","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1177\/2040620715576662","volume":"6","author":"A Chaidos","year":"2015","unstructured":"Chaidos, A., Caputo, V. & Karadimitris, A. Inhibition of bromodomain and extra-terminal proteins (BET) as a potential therapeutic approach in haematological malignancies: emerging preclinical and clinical evidence. Therapeutic advances in hematology 6, 128\u2013141, https:\/\/doi.org\/10.1177\/2040620715576662 (2015).","journal-title":"Therapeutic advances in hematology"},{"key":"26496_CR17","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1021\/acs.jmedchem.5b01708","volume":"59","author":"B Raux","year":"2016","unstructured":"Raux, B. et al. Exploring Selective Inhibition of the First Bromodomain of the Human Bromodomain and Extra-terminal Domain (BET) Proteins. Journal of medicinal chemistry 59, 1634\u20131641, https:\/\/doi.org\/10.1021\/acs.jmedchem.5b01708 (2016).","journal-title":"Journal of medicinal chemistry"},{"key":"26496_CR18","doi-asserted-by":"publisher","first-page":"5501","DOI":"10.18632\/oncotarget.3551","volume":"6","author":"LL Fu","year":"2015","unstructured":"Fu, L. L. et al. Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery. Oncotarget 6, 5501\u20135516, https:\/\/doi.org\/10.18632\/oncotarget.3551 (2015).","journal-title":"Oncotarget"},{"key":"26496_CR19","doi-asserted-by":"publisher","first-page":"16669","DOI":"10.1073\/pnas.1108190108","volume":"108","author":"JA Mertz","year":"2011","unstructured":"Mertz, J. A. et al. Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proceedings of the National Academy of Sciences of the United States of America 108, 16669\u201316674, https:\/\/doi.org\/10.1073\/pnas.1108190108 (2011).","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"26496_CR20","doi-asserted-by":"publisher","first-page":"7498","DOI":"10.1021\/jm4014407","volume":"56","author":"Y Zhao","year":"2013","unstructured":"Zhao, Y., Yang, C. Y. & Wang, S. The making of I-BET762, a BET bromodomain inhibitor now in clinical development. Journal of medicinal chemistry 56, 7498\u20137500, https:\/\/doi.org\/10.1021\/jm4014407 (2013).","journal-title":"Journal of medicinal chemistry"},{"key":"26496_CR21","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1182\/blood-2013-01-478420","volume":"123","author":"A Chaidos","year":"2014","unstructured":"Chaidos, A. et al. Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762. Blood 123, 697\u2013705, https:\/\/doi.org\/10.1182\/blood-2013-01-478420 (2014).","journal-title":"Blood"},{"key":"26496_CR22","doi-asserted-by":"publisher","first-page":"7501","DOI":"10.1021\/jm401088k","volume":"56","author":"O Mirguet","year":"2013","unstructured":"Mirguet, O. et al. Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains. Journal of medicinal chemistry 56, 7501\u20137515, https:\/\/doi.org\/10.1021\/jm401088k (2013).","journal-title":"Journal of medicinal chemistry"},{"key":"26496_CR23","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.canlet.2017.02.021","volume":"394","author":"AS Leal","year":"2017","unstructured":"Leal, A. S. et al. Bromodomain inhibitors, JQ1 and I-BET 762, as potential therapies for pancreatic cancer. Cancer letters 394, 76\u201387, https:\/\/doi.org\/10.1016\/j.canlet.2017.02.021 (2017).","journal-title":"Cancer letters"},{"key":"26496_CR24","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1038\/nrc.2016.80","volume":"16","author":"S Seton-Rogers","year":"2016","unstructured":"Seton-Rogers, S. Pancreatic cancer: Dodging immunosuppression. Nature reviews. Cancer 16, 480\u2013481, https:\/\/doi.org\/10.1038\/nrc.2016.80 (2016).","journal-title":"Nature reviews. Cancer"},{"key":"26496_CR25","doi-asserted-by":"publisher","first-page":"479","DOI":"10.21037\/jgo.2015.10.01","volume":"7","author":"SK Kim","year":"2016","unstructured":"Kim, S. K., Wu, C. C. & Horowitz, D. P. Stereotactic body radiotherapy for the pancreas: a critical review for the medical oncologist. Journal of gastrointestinal oncology 7, 479\u2013486, https:\/\/doi.org\/10.21037\/jgo.2015.10.01 (2016).","journal-title":"Journal of gastrointestinal oncology"},{"key":"26496_CR26","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1038\/nm.4378","volume":"23","author":"X Dai","year":"2017","unstructured":"Dai, X. et al. Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4. Nature medicine 23, 1063\u20131071, https:\/\/doi.org\/10.1038\/nm.4378 (2017).","journal-title":"Nature medicine"},{"key":"26496_CR27","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1038\/nm.3952","volume":"21","author":"PK Mazur","year":"2015","unstructured":"Mazur, P. K. et al. Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma. Nature medicine 21, 1163\u20131171, https:\/\/doi.org\/10.1038\/nm.3952 (2015).","journal-title":"Nature medicine"},{"key":"26496_CR28","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1038\/cr.2014.90","volume":"24","author":"PG Alluri","year":"2014","unstructured":"Alluri, P. G., Asangani, I. A. & Chinnaiyan, A. M. BETs abet Tam-R in ER-positive breast cancer. Cell research 24, 899\u2013900, https:\/\/doi.org\/10.1038\/cr.2014.90 (2014).","journal-title":"Cell research"},{"key":"26496_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/nm.4341","volume":"23","author":"DS Rickman","year":"2017","unstructured":"Rickman, D. S., Beltran, H., Demichelis, F. & Rubin, M. A. Biology and evolution of poorly differentiated neuroendocrine tumors. Nature medicine 23, 1\u201310, https:\/\/doi.org\/10.1038\/nm.4341 (2017).","journal-title":"Nature medicine"},{"key":"26496_CR30","first-page":"2191","volume":"32","author":"R Klapdor","year":"2012","unstructured":"Klapdor, R., Klapdor, S. & Bahlo, M. Combination therapy with gemcitabine (GEM) and erlotinib (E) in exocrine pancreatic cancer under special reference to RASH and the tumour marker CA19-9. Anticancer research 32, 2191\u20132197 (2012).","journal-title":"Anticancer research"},{"key":"26496_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-016-2482-z","volume":"16","author":"S Shin","year":"2016","unstructured":"Shin, S., Park, C. M., Kwon, H. & Lee, K. H. Erlotinib plus gemcitabine versus gemcitabine for pancreatic cancer: real-world analysis of Korean national database. BMC cancer 16, 443, https:\/\/doi.org\/10.1186\/s12885-016-2482-z (2016).","journal-title":"BMC cancer"},{"key":"26496_CR32","first-page":"5211","volume":"29","author":"A Ardavanis","year":"2009","unstructured":"Ardavanis, A. et al. Biweekly gemcitabine (GEM) in combination with erlotinib (ERL): an active and convenient regimen for advanced pancreatic cancer. Anticancer research 29, 5211\u20135217 (2009).","journal-title":"Anticancer research"},{"key":"26496_CR33","doi-asserted-by":"publisher","first-page":"487","DOI":"10.2217\/epi.14.91","volume":"7","author":"M Jung","year":"2015","unstructured":"Jung, M., Gelato, K. A., Fernandez-Montalvan, A., Siegel, S. & Haendler, B. Targeting BET bromodomains for cancer treatment. Epigenomics 7, 487\u2013501, https:\/\/doi.org\/10.2217\/epi.14.91 (2015).","journal-title":"Epigenomics"},{"key":"26496_CR34","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/onc.2016.247","volume":"36","author":"J Tong","year":"2017","unstructured":"Tong, J., Tan, S., Zou, F., Yu, J. & Zhang, L. FBW7 mutations mediate resistance of colorectal cancer to targeted therapies by blocking Mcl-1 degradation. Oncogene 36, 787\u2013796, https:\/\/doi.org\/10.1038\/onc.2016.247 (2017).","journal-title":"Oncogene"},{"key":"26496_CR35","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1038\/onc.2015.216","volume":"35","author":"E Hessmann","year":"2016","unstructured":"Hessmann, E., Schneider, G., Ellenrieder, V. & Siveke, J. T. MYC in pancreatic cancer: novel mechanistic insights and their translation into therapeutic strategies. Oncogene 35, 1609\u20131618, https:\/\/doi.org\/10.1038\/onc.2015.216 (2016).","journal-title":"Oncogene"},{"key":"26496_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/srep09489","volume":"5","author":"K Kumar","year":"2015","unstructured":"Kumar, K. et al. GLI2-dependent c-MYC upregulation mediates resistance of pancreatic cancer cells to the BET bromodomain inhibitor JQ1. Scientific reports 5, 9489, https:\/\/doi.org\/10.1038\/srep09489 (2015).","journal-title":"Scientific reports"},{"key":"26496_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/srep20390","volume":"6","author":"A Nakagawa","year":"2016","unstructured":"Nakagawa, A. et al. Selective and reversible suppression of intestinal stem cell differentiation by pharmacological inhibition of BET bromodomains. Scientific reports 6, 20390, https:\/\/doi.org\/10.1038\/srep20390 (2016).","journal-title":"Scientific reports"},{"key":"26496_CR38","doi-asserted-by":"publisher","first-page":"61469","DOI":"10.18632\/oncotarget.11129","volume":"7","author":"K Yamamoto","year":"2016","unstructured":"Yamamoto, K. et al. Stromal remodeling by the BET bromodomain inhibitor JQ1 suppresses the progression of human pancreatic cancer. Oncotarget 7, 61469\u201361484, https:\/\/doi.org\/10.18632\/oncotarget.11129 (2016).","journal-title":"Oncotarget"},{"key":"26496_CR39","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1158\/1535-7163.MCT-17-0032","volume":"16","author":"J Tong","year":"2017","unstructured":"Tong, J. et al. FBW7-Dependent Mcl-1 Degradation Mediates the Anticancer Effect of Hsp90 Inhibitors. Molecular cancer therapeutics 16, 1979\u20131988, https:\/\/doi.org\/10.1158\/1535-7163.MCT-17-0032 (2017).","journal-title":"Molecular cancer therapeutics"},{"key":"26496_CR40","doi-asserted-by":"publisher","first-page":"2512","DOI":"10.1158\/0008-5472.CAN-16-3242","volume":"77","author":"J Tong","year":"2017","unstructured":"Tong, J. et al. Mcl-1 Degradation Is Required for Targeted Therapeutics to Eradicate Colon Cancer Cells. Cancer research 77, 2512\u20132521, https:\/\/doi.org\/10.1158\/0008-5472.CAN-16-3242 (2017).","journal-title":"Cancer research"}],"updated-by":[{"DOI":"10.1038\/s41598-023-48298-9","type":"retraction","label":"Retraction","source":"retraction-watch","updated":{"date-parts":[[2023,11,28]],"date-time":"2023-11-28T00:00:00Z","timestamp":1701129600000},"record-id":"49739"},{"DOI":"10.1038\/s41598-023-48298-9","type":"retraction","label":"Retraction","source":"publisher","updated":{"date-parts":[[2023,11,28]],"date-time":"2023-11-28T00:00:00Z","timestamp":1701129600000}}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-26496-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-26496-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-26496-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T09:03:30Z","timestamp":1701248610000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-26496-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,25]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["26496"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-26496-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,25]]},"assertion":[{"value":"6 December 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2023","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article has been retracted. Please see the Retraction Notice for more detail:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41598-023-48298-9","URL":"https:\/\/doi.org\/10.1038\/s41598-023-48298-9","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"8102"}}